OCUP vs. CLRB, TRVI, PBYI, TELO, CAPR, RIGL, RPTX, OGI, GALT, and ALIM
Should you be buying Ocuphire Pharma stock or one of its competitors? The main competitors of Ocuphire Pharma include Cellectar Biosciences (CLRB), Trevi Therapeutics (TRVI), Puma Biotechnology (PBYI), Telomir Pharmaceuticals (TELO), Capricor Therapeutics (CAPR), Rigel Pharmaceuticals (RIGL), Repare Therapeutics (RPTX), Organigram (OGI), Galectin Therapeutics (GALT), and Alimera Sciences (ALIM). These companies are all part of the "pharmaceutical preparations" industry.
Ocuphire Pharma (NASDAQ:OCUP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation.
Ocuphire Pharma has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Ocuphire Pharma has higher revenue and earnings than Cellectar Biosciences. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Cellectar Biosciences has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -59.44%. Ocuphire Pharma's return on equity of -24.57% beat Cellectar Biosciences' return on equity.
15.0% of Ocuphire Pharma shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 8.7% of Ocuphire Pharma shares are owned by insiders. Comparatively, 3.7% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cellectar Biosciences received 206 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. However, 68.00% of users gave Ocuphire Pharma an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
In the previous week, Ocuphire Pharma had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 1 mentions for Ocuphire Pharma and 0 mentions for Cellectar Biosciences. Ocuphire Pharma's average media sentiment score of 0.00 equaled Cellectar Biosciences'average media sentiment score.
Ocuphire Pharma currently has a consensus price target of $18.75, indicating a potential upside of 1,009.47%. Cellectar Biosciences has a consensus price target of $20.00, indicating a potential upside of 500.60%. Given Ocuphire Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Ocuphire Pharma is more favorable than Cellectar Biosciences.
Summary
Ocuphire Pharma beats Cellectar Biosciences on 12 of the 17 factors compared between the two stocks.
Get Ocuphire Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocuphire Pharma Competitors List
Related Companies and Tools
